Lifecore Biomedical Stock Total Debt
| LFCR Stock | 5.87 0.10 1.73% |
Lifecore Biomedical fundamentals help investors to digest information that contributes to Lifecore Biomedical's financial success or failures. It also enables traders to predict the movement of Lifecore Stock. The fundamental analysis module provides a way to measure Lifecore Biomedical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lifecore Biomedical stock.
As of 05/20/2024, Total Debt To Capitalization is likely to drop to 0.18. Lifecore | Total Debt |
Lifecore Biomedical Company Total Debt Analysis
Lifecore Biomedical's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Lifecore Biomedical Total Debt | 153.09 M |
Most of Lifecore Biomedical's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lifecore Biomedical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Lifecore Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Lifecore Biomedical is extremely important. It helps to project a fair market value of Lifecore Stock properly, considering its historical fundamentals such as Total Debt. Since Lifecore Biomedical's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lifecore Biomedical's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lifecore Biomedical's interrelated accounts and indicators.
Click cells to compare fundamentals
Lifecore Total Debt Historical Pattern
Today, most investors in Lifecore Biomedical Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Lifecore Biomedical's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Lifecore Biomedical total debt as a starting point in their analysis.
Lifecore Biomedical Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Lifecore Short Long Term Debt Total
Short Long Term Debt Total |
|
Based on the latest financial disclosure, Lifecore Biomedical has a Total Debt of 153.09 M. This is 94.44% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The total debt for all United States stocks is 97.12% higher than that of the company.
Lifecore Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lifecore Biomedical's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lifecore Biomedical could also be used in its relative valuation, which is a method of valuing Lifecore Biomedical by comparing valuation metrics of similar companies.Lifecore Biomedical is currently under evaluation in total debt category among related companies.
Lifecore Biomedical ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Lifecore Biomedical's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Lifecore Biomedical's managers, analysts, and investors.Environmental | Governance | Social |
Lifecore Biomedical Institutional Holders
Institutional Holdings refers to the ownership stake in Lifecore Biomedical that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Lifecore Biomedical's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Lifecore Biomedical's value.| Shares | Deutsche Bank Ag | 2023-12-31 | 315.7 K | Geode Capital Management, Llc | 2023-12-31 | 285.1 K | Dcf Advisers, Llc | 2023-12-31 | 259.7 K | Susquehanna International Group, Llp | 2023-12-31 | 226 K | Qube Research & Technologies | 2023-12-31 | 147.4 K | Marshall Wace Asset Management Ltd | 2023-12-31 | 143.9 K | Jane Street Group, Llc | 2023-12-31 | 136.2 K | Citigroup Inc | 2024-03-31 | 128.6 K | State Street Corporation | 2023-12-31 | 118.8 K | Wynnefield Capital Inc | 2024-03-31 | 4.9 M | Legion Partners Asset Management, Llc | 2024-03-31 | 3 M |
Lifecore Fundamentals
| Return On Equity | -1.05 | ||||
| Return On Asset | -0.0467 | ||||
| Profit Margin | (0.96) % | ||||
| Operating Margin | (0.08) % | ||||
| Current Valuation | 377.06 M | ||||
| Shares Outstanding | 30.55 M | ||||
| Shares Owned By Insiders | 4.53 % | ||||
| Shares Owned By Institutions | 75.76 % | ||||
| Number Of Shares Shorted | 1.98 M | ||||
| Price To Book | 1.57 X | ||||
| Price To Sales | 1.79 X | ||||
| Revenue | 185.79 M | ||||
| Gross Profit | 27.29 M | ||||
| EBITDA | 21.25 M | ||||
| Net Income | (97.24 M) | ||||
| Total Debt | 153.09 M | ||||
| Book Value Per Share | (0.14) X | ||||
| Cash Flow From Operations | (24.4 M) | ||||
| Short Ratio | 10.91 X | ||||
| Earnings Per Share | (2.14) X | ||||
| Price To Earnings To Growth | 3.51 X | ||||
| Target Price | 8.0 | ||||
| Number Of Employees | 459 | ||||
| Beta | 0.98 | ||||
| Market Capitalization | 179.31 M | ||||
| Total Asset | 295.44 M | ||||
| Retained Earnings | (58.66 M) | ||||
| Working Capital | 60.48 M | ||||
| Net Asset | 295.44 M |
About Lifecore Biomedical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lifecore Biomedical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lifecore Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lifecore Biomedical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Lifecore Biomedical Piotroski F Score and Lifecore Biomedical Altman Z Score analysis. To learn how to invest in Lifecore Stock, please use our How to Invest in Lifecore Biomedical guide.Note that the Lifecore Biomedical information on this page should be used as a complementary analysis to other Lifecore Biomedical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for Lifecore Stock analysis
When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Stocks Directory Find actively traded stocks across global markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
Is Lifecore Biomedical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lifecore Biomedical. If investors know Lifecore will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lifecore Biomedical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.14) | Revenue Per Share 3.447 | Quarterly Revenue Growth 0.208 | Return On Assets (0.05) | Return On Equity (1.05) |
The market value of Lifecore Biomedical is measured differently than its book value, which is the value of Lifecore that is recorded on the company's balance sheet. Investors also form their own opinion of Lifecore Biomedical's value that differs from its market value or its book value, called intrinsic value, which is Lifecore Biomedical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lifecore Biomedical's market value can be influenced by many factors that don't directly affect Lifecore Biomedical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lifecore Biomedical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lifecore Biomedical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lifecore Biomedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.